The Conversation (0)
Neptune Technologies & Bioressources announced a new exclusive licensing agreement for the use of the MaxSimil technology in combination with cannabis-derived products.
Neptune Technologies & Bioressources (NASDAQ:NEPT; TSX:NEPT) announced a new exclusive licensing agreement for the use of the MaxSimil technology in combination with cannabis-derived products.
As quoted in the press release:
This new agreement allows Neptune to research, manufacture, formulate, distribute and sell monoglyceride omega-3-rich ingredients in combination with cannabis and/or cannabinoid-rich hemp-derived ingredients for medical and adult use applications.
As indicated in the past, the Company believes the MaxSimil® technology has the ability to enhance absorption of lipid-based and lipid soluble ingredients such as cannabinoids, essential fatty acids including EPA and DHA omega-3s, vitamins A, D, K and E, CoQ10 and others. This could be especially beneficial in increasing the absorption of ingredients which are not easily absorbed, such as cannabidiol (CBD).
“Neptune’s strategy is to position itself in segments characterized by size and growth and the legal cannabis industry fits well with this and our wellness mission. Our core competencies in science, regulatory affairs, formulation, commercialization and oil extraction are tremendous foundations to position ourselves for success. Over the past year, MaxSimil® has been a proven winner in our Solutions Business and we are excited to apply this technology to cannabis-derived products. We will now begin investigating the impact of this innovative technology on the absorption and benefits of cannabis and cannabinoid ingredients,” said Jim Hamilton, President & CEO of Neptune.
Click here to read the full press release.
Source: www.marketwired.com
